Parallax Volatility Advisers L.P. Purchases New Position in Cronos Group Inc. $CRON

Key Points

• Parallax Volatility Advisers purchased 300,000 Cronos Group shares worth approximately $834,000, while institutional investors collectively own 8.71% of the company.
• Cronos Group shares rose 1.1% to $3.55, near their 52-week high of $3.58. The company recently reported quarterly EPS of $0.09 and revenue of $53.01 million, exceeding analyst expectations.
• Analyst sentiment remains cautious, with two Buy ratings and three Hold ratings; the consensus rating is Hold with an average price target of $2.30.

Parallax Volatility Advisers L.P. purchased a new stake in Cronos Group Inc. (NASDAQ:CRON - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 300,000 shares of the company's stock, valued at approximately $834,000. Parallax Volatility Advisers L.P. owned 0.08% of Cronos Group as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC bought a new stake in Cronos Group in the 2nd quarter valued at $29,000. Brooklyn Investment Group lifted its holdings in shares of Cronos Group by 5,733.0% during the third quarter. Brooklyn Investment Group now owns 10,966 shares of the company's stock worth $30,000 after buying an additional 10,778 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of Cronos Group in the fourth quarter valued at about $30,000. Scientech Research LLC acquired a new position in shares of Cronos Group in the third quarter valued at about $32,000. Finally, Sender Co & Partners Inc. bought a new position in Cronos Group during the third quarter worth about $35,000. Institutional investors own 8.71% of the company's stock.

Cronos Group Trading Up 1.1%

NASDAQ CRON opened at $3.55 on Thursday. The firm's 50 day simple moving average is $2.92 and its 200 day simple moving average is $2.74. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of 17.75 and a beta of 0.90. Cronos Group Inc. has a 1 year low of $2.28 and a 1 year high of $3.58.

Cronos Group (NASDAQ:CRON - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.01 by $0.08. The business had revenue of $53.01 million during the quarter, compared to the consensus estimate of $44.20 million. Cronos Group had a net margin of 39.08% and a return on equity of 4.85%. On average, equities research analysts forecast that Cronos Group Inc. will post 0.11 earnings per share for the current year.

Analyst Ratings Changes

CRON has been the topic of a number of analyst reports. TD Securities restated a "buy" rating on shares of Cronos Group in a research report on Tuesday, May 12th. Weiss Ratings raised Cronos Group from a "sell (d+)" rating to a "hold (c+)" rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen lowered Cronos Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $2.30.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group's business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company's branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.